{"id":"ampicillin-gentamicin-or-cefotaxime-gentamicin","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity (aminoglycoside-related)"},{"rate":null,"effect":"Ototoxicity (aminoglycoside-related)"},{"rate":null,"effect":"Allergic reactions (beta-lactam-related)"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis. Gentamicin is an aminoglycoside that inhibits bacterial protein synthesis. Cefotaxime is a third-generation cephalosporin that also inhibits cell wall synthesis. The combination provides synergistic activity and broader coverage than monotherapy, particularly useful in serious infections where empiric coverage is needed before culture results are available.","oneSentence":"This combination regimen uses two or three antibiotics with different mechanisms to provide broad-spectrum coverage against gram-positive, gram-negative, and anaerobic bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:03.083Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neonatal sepsis and serious bacterial infections in newborns"},{"name":"Empiric treatment of suspected gram-positive and gram-negative bacterial infections in pediatric populations"}]},"trialDetails":[{"nctId":"NCT06712641","phase":"PHASE4","title":"Aminoglycosides in Early Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2026-04","conditions":"Sepsis","enrollment":1900},{"nctId":"NCT02701595","phase":"PHASE3","title":"Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2016-02-29","conditions":"Infective Endocarditis","enrollment":324},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":"Febrile Urinary Tract Infection","enrollment":560},{"nctId":"NCT04041791","phase":"PHASE3","title":"A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-08-19","conditions":"Pneumonia","enrollment":4392},{"nctId":"NCT02784821","phase":"PHASE2","title":"Antibiotic \"Dysbiosis\" in Preterm Infants","status":"COMPLETED","sponsor":"University of Florida","startDate":"2017-01-16","conditions":"Enterocolitis, Necrotizing, Bacteremia, Bronchopulmonary Dysplasia","enrollment":98},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT03560232","phase":"PHASE4","title":"Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens","status":"TERMINATED","sponsor":"Mercy Health Ohio","startDate":"2018-07-09","conditions":"Open Fracture, Post-Op Wound Infection","enrollment":17},{"nctId":"NCT03174236","phase":"PHASE3","title":"First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2017-09-04","conditions":"Malnutrition Severe, Antibiotic Resistance, Antibiotic Toxicity","enrollment":2000},{"nctId":"NCT01551394","phase":"PHASE3","title":"Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2012-09","conditions":"Sepsis","enrollment":272},{"nctId":"NCT01559753","phase":"PHASE4","title":"Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"1998-01","conditions":"Pneumonia Ventilator Associated","enrollment":225}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6808,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ampicillin sodium","Gentamicin sulphate","Cefotaxime sodium"],"phase":"phase_3","status":"active","brandName":"Ampicillin + gentamicin or cefotaxime + gentamicin","genericName":"Ampicillin + gentamicin or cefotaxime + gentamicin","companyName":"PENTA Foundation","companyId":"penta-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses two or three antibiotics with different mechanisms to provide broad-spectrum coverage against gram-positive, gram-negative, and anaerobic bacteria. Used for Neonatal sepsis and serious bacterial infections in newborns, Empiric treatment of suspected gram-positive and gram-negative bacterial infections in pediatric populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}